Related Experiment Video
Updated: Apr 26, 2026
09:28
Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation
Published on: May 18, 2020
8.0K
The Evolution of quality by design (QbD) for biologics
1Principal Consultant, PAREXEL International, Uxbridge, Middlesex, UK anthony.newcombe@parexel.com.
PDA Journal of Pharmaceutical Science and Technology
|July 19, 2014
Summary
Regulatory bodies are enhancing controls in drug manufacturing. This commentary discusses design space verification within quality by design, a key strategy for improved drug development.
Area of Science:
- Pharmaceutical Sciences
- Regulatory Science
- Drug Manufacturing
Background:
- Increasing regulatory focus on enhanced controls in pharmaceutical manufacturing.
- Quality by Design (QbD) as a science- and risk-based approach to drug development.
- Ongoing pilot programs evaluating advanced drug development strategies.
Purpose of the Study:
- To provide a commentary on a recent regulatory publication concerning design space verification.
- To discuss the implications of design space verification in the context of Quality by Design.
- To highlight the importance of robust verification methods in drug product development.
Main Methods:
- Commentary on a specific regulatory publication.
- Analysis of Quality by Design principles related to design space verification.
- Review of current regulatory perspectives on enhanced drug development.
Main Results:
- The commentary emphasizes the critical role of design space verification in ensuring drug product quality and consistency.
- It highlights the need for clear regulatory guidance on design space verification methodologies.
- The article underscores the potential of QbD and verified design spaces to streamline drug development.
Conclusions:
- Design space verification is essential for successful implementation of Quality by Design.
- Further regulatory dialogue and clarification are needed to support effective design space verification.
- Adoption of QbD principles, including robust verification, can lead to more efficient and reliable drug manufacturing.
More Related Videos
05:45Author Spotlight: Process Development for the Spray-Drying of Probiotic Bacteria and Evaluation of the Product Quality
Published on: April 7, 2023
4.4K
10:50Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System
Published on: May 1, 2019
17.3K
Related Concept Videos
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
541
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
541
01:28Drug Products: Biologics, Biosimilars and Interchangeables
369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
01:27Upstream Processing
95
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
95
01:13Bioequivalence studies: Biowaivers
429
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
429
01:22Bioreactor Controls-III
67
Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...
67
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226